Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference

Rhea-AI Summary

Myriad Genetics, a leader in genetic testing, will participate in the 42nd Annual Cowen Health Care Conference on March 8, 2022, at 9:50 a.m. ET. CEO Paul J. Diaz will discuss the impact of genetic insights on health equity, new commercial capabilities, and industry trends. The presentation will be available via a live audio webcast on Myriad's investor information page at www.myriad.com. Myriad Genetics is dedicated to improving patient care through genetic testing that influences disease risk assessment and treatment decisions.

SALT LAKE CITY, March 02, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be participating in a fireside chat at the 42^nd Annual Cowen Health Care Conference on March 8, 2022 at 9:50 a.m. ET.

Diaz will share insights on the growing role of genetic insights in context with industry trends, new commercial capabilities and products that advance health equity and enable healthcare providers to better detect, treat and prevent disease.

The presentation will be available through a live audio webcast link on the investor information section of Myriad’s website at www.myriad.com.  

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the company's website: www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, ColarisAP, MyRisk, Myriad myRisk, MyRisk Hereditary Cancer, myChoice, Tumor BRACAnalysis CDx, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, Health.Illuminated., RiskScore, Prolaris, GeneSight, FirstGene and EndoPredict are registered trademarks or trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

Media Contact:
Megan Manzari
(385) 318-3718
Megan.Manzari@myriad.com

Investor Contact:
Nathan Smith
(801) 505-5067
Nathan.Smith@myriad.com 

FAQ

What is Myriad Genetics' participation in the 42nd Annual Cowen Health Care Conference?

Myriad Genetics will be represented by CEO Paul J. Diaz at the 42nd Annual Cowen Health Care Conference on March 8, 2022, at 9:50 a.m. ET.

What topics will be covered by Myriad Genetics at the conference?

Paul J. Diaz will discuss the growing role of genetic insights, new commercial capabilities, and industry trends related to health equity.

How can I access Myriad Genetics' conference presentation?

The presentation will be available through a live audio webcast on Myriad's investor information section at www.myriad.com.

What does Myriad Genetics specialize in?

Myriad Genetics specializes in genetic testing and precision medicine, focusing on improving patient care and reducing healthcare costs.

When will the Cowen Health Care Conference take place?

The Cowen Health Care Conference will take place on March 8, 2022.

Which stock symbol represents Myriad Genetics?

Myriad Genetics is listed under the stock symbol MYGN.